EA201690686A1 - Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита - Google Patents
Способ профилактики или лечения системной красной волчанки и/или волчаночного нефритаInfo
- Publication number
- EA201690686A1 EA201690686A1 EA201690686A EA201690686A EA201690686A1 EA 201690686 A1 EA201690686 A1 EA 201690686A1 EA 201690686 A EA201690686 A EA 201690686A EA 201690686 A EA201690686 A EA 201690686A EA 201690686 A1 EA201690686 A1 EA 201690686A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lupine
- jade
- prevention
- treatment
- systemic red
- Prior art date
Links
- 241000219745 Lupinus Species 0.000 title 1
- 239000010977 jade Substances 0.000 title 1
- 206010025135 lupus erythematosus Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
- -1 {[(2,5-dichlorobenzoyl) amino] acetyl} amino Chemical group 0.000 abstract 2
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886403P | 2013-10-03 | 2013-10-03 | |
| PCT/US2014/058738 WO2015051067A1 (en) | 2013-10-03 | 2014-10-02 | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201690686A1 true EA201690686A1 (ru) | 2016-08-31 |
Family
ID=51842818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690686A EA201690686A1 (ru) | 2013-10-03 | 2014-10-02 | Способ профилактики или лечения системной красной волчанки и/или волчаночного нефрита |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160250238A1 (enExample) |
| EP (1) | EP3052105A1 (enExample) |
| JP (1) | JP2016531886A (enExample) |
| KR (1) | KR20160058886A (enExample) |
| CN (1) | CN105705149A (enExample) |
| BR (1) | BR112016007237A2 (enExample) |
| CA (1) | CA2925935A1 (enExample) |
| EA (1) | EA201690686A1 (enExample) |
| MX (1) | MX2016003979A (enExample) |
| WO (1) | WO2015051067A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020000092A1 (en) * | 2018-06-27 | 2020-01-02 | Algernon Pharmaceuticals Inc. | The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease |
| CN115515578A (zh) * | 2020-05-07 | 2022-12-23 | 诺罗瑞韦有限公司 | 用于治疗抑郁症的环丝氨酸和己酮可可碱联合疗法 |
| CN121041156A (zh) * | 2025-08-27 | 2025-12-02 | 复皙药业(上海)有限公司 | 含有替普瑞酮的具有祛红功效的膏霜及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CA2435146C (en) | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| KR20140042933A (ko) * | 2007-08-06 | 2014-04-07 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 프로테아좀 억제제 |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| SI2318419T2 (sl) * | 2008-06-17 | 2025-10-30 | Takeda Pharmaceutical Company Limited | Spojine boronat estra in njihovi farmacevtski sestavki |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| TW201309303A (zh) * | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
| WO2012177835A1 (en) * | 2011-06-22 | 2012-12-27 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
-
2014
- 2014-10-02 US US15/026,417 patent/US20160250238A1/en not_active Abandoned
- 2014-10-02 EA EA201690686A patent/EA201690686A1/ru unknown
- 2014-10-02 MX MX2016003979A patent/MX2016003979A/es unknown
- 2014-10-02 KR KR1020167010114A patent/KR20160058886A/ko not_active Withdrawn
- 2014-10-02 WO PCT/US2014/058738 patent/WO2015051067A1/en not_active Ceased
- 2014-10-02 CA CA2925935A patent/CA2925935A1/en not_active Abandoned
- 2014-10-02 CN CN201480060987.4A patent/CN105705149A/zh active Pending
- 2014-10-02 JP JP2016519782A patent/JP2016531886A/ja active Pending
- 2014-10-02 BR BR112016007237A patent/BR112016007237A2/pt not_active IP Right Cessation
- 2014-10-02 EP EP14790872.7A patent/EP3052105A1/en not_active Withdrawn
-
2017
- 2017-12-12 US US15/838,595 patent/US20180099000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2925935A1 (en) | 2015-04-09 |
| MX2016003979A (es) | 2016-06-15 |
| BR112016007237A2 (pt) | 2017-09-12 |
| US20180099000A1 (en) | 2018-04-12 |
| WO2015051067A1 (en) | 2015-04-09 |
| JP2016531886A (ja) | 2016-10-13 |
| EP3052105A1 (en) | 2016-08-10 |
| KR20160058886A (ko) | 2016-05-25 |
| CN105705149A (zh) | 2016-06-22 |
| US20160250238A1 (en) | 2016-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| PH12019501339A1 (en) | Amino acid compositions and methods for the treatment of muscle diseases and disorders | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| MX377629B (es) | Composiciones farmacéuticas tópicas. | |
| IN2015DN00376A (enExample) | ||
| PH12016502355B1 (en) | Pharmaceutical composition | |
| IN2015DN00450A (enExample) | ||
| MX2021013880A (es) | Polimeros enlazados al proton para administracion oral. | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| EA201500851A1 (ru) | ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3) | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| EA201591378A1 (ru) | Композиции неорганических наночастиц в комбинации с ионизирующим излучением для лечения рака | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX380968B (es) | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| EP4219534A3 (en) | Methods for treatment of and prophylaxis against inflammatory disorders | |
| CN106456621A8 (zh) | 用于治疗hcv的方法 | |
| MX2016003979A (es) | Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. | |
| MY184269A (en) | Broad-spectrum anti-influenza virus therapeutic peptides | |
| EA201690070A1 (ru) | Применение аргинина и/или цитруллина для лечения и/или профилактики остеоартроза |